• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott warns on electromagnetic interference in some Aveir leadless pacemakers

Abbott warns on electromagnetic interference in some Aveir leadless pacemakers

April 5, 2024 By Danielle Kirsh

Abbott Aveir single-chamber (VR) leadless pacemaker
The Aveir single-chamber (VR) leadless pacemaker [Image courtesy of Abbott]
Abbott (NYSE: ABT) recently issued an urgent field safety notice warning physicians that some Aveir leadless pacemakers may have electromagnetic interference.

The Abbott Park, Illinois-based company warned that a subset of Aveir VR LSP112V devices manufactured with firmware version 19.05.00 have the potential for electromagnetic interference that could cause an inadvertent mode change.

So far, the company said there have been no reports of permanent patient harm due to the issue. Two devices have been replaced due to early detection of the recommended replacement time (RRT).

The mode change can be detected during a Merlin programmer interrogation session, as the Aveir VR device could potentially be in Emergency VVI (EVVI) or MRI (VOO) mode. Since communication with the implanted Aveir requires a Merlin programmer, the issue can be detected at a scheduled in-clinic follow-up unless symptoms are present at an earlier evaluation, the urgent field safety notice said.

Abbott noted that the issue may cause an Aveir VR device to enter either EVVI or MRI mode. The parameters for EVVI mode are VVI pacing at 6 V @ 0.6 ms and 70 bpm, and MRI mode is VOO mode at 5 V @ 1 ms and 85 bpm. Compared to the nominal settings, the increased pacing output and rate of the modes may reduce the longevity of some leadless pacemakers.

Affected devices and recommendations from Abbott

Approximately 12,000 Aveir VR devices are subject to this notification with two patient effects reported. Four patients have reported the sensation of an elevated heart rate consistent with a mode change, according to Abbott. Two devices also showed early detection of RRT and were replaced.

Abbott estimates that 8% of the longevity of Aveir VR devices operating in MRI or EVVI mode is consumed for each month of operation.The service life of a device operating entirely in EVVI or MRI mode is approximately 13 months.

To mitigate the issue, Abbott said upgraded Merlin PCS 3650 programmer software will download new firmware version 19.12.00 for Aveir through an automatic prompt to the user during an in-clinic evaluation. All device settings and therapies will remain active during the firmware download.

The programmer software and updated firmware will be available to clinics this month.

Abbott does not recommend prophylactic device replacement. As part of the suggested three-month follow-up, Abbott recommends updating the Aveir VR’s firmware. For most devices, the upgrade should automatically download. If the device has shown to have been in MRI or EVVI mode, reprogram it to the desired mode and settings.

Medical Design & Outsourcing: How Abbott designed the world’s first dual-chamber leadless pacemaker system

Filed Under: Cardiac Implants, Cardiovascular, Recalls, Regulatory/Compliance Tagged With: Abbott

More recent news

  • J&J launches faster Shockwave coronary catheter in the US
  • Abbott’s Cologuard Plus screening test receives CE Mark
  • Haemonetics wins FDA approval of PerQseal Elite vascular closure system
  • Medtronic announces a company president
  • Medtronic nets CE mark for Vitalis family of conduction system pacemakers

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy